Intestinal neoplasm

Summary

Intestinal neoplasm (MONDO:0021118) is a cancer (an umbrella term covering 6 Mondo subtypes) and 27 clinical trials. Top therapeutic interventions include alectinib, irinotecan hydrochloride, and pralsetinib. A subtype of intestinal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 6 Mondo subtypes
• Clinical trials: 27

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intestinal neoplasm
Mondo ID	MONDO:0021118
DOID	DOID:4610
NCIT	C3141
SNOMED CT	126769007
UMLS	C0021841
MedGen	43932
Anatomy (UBERON)	UBERON:0000160
Is cancer (heuristic)	yes

Also known as: bowel neoplasm · intestinal neoplasm · intestinal neoplasms · intestinal tumor · intestinal tumors · intestinal tumour · intestinal tumours · intestine neoplasm · intestine neoplasm (disease) · intestine tumor · intestine tumour · neoplasm of intestine · neoplasm of intestines · neoplasm of the intestines · tumor of intestine · tumor of intestines · tumor of the intestines · tumour of intestine · tumour of intestines · tumour of the intestines

Disease family

This is a subtype of intestinal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal neoplasm

Related subtypes (57): intestinal atresia, steatorrhea, angiodysplasia of intestine, endometriosis of intestine, hypertrophic pyloric stenosis, mucocele of appendix, gastroenteritis, diverticulitis, intestinal obstruction, postgastrectomy syndrome, chronic intestinal vascular insufficiency, bowel dysfunction, irritable bowel syndrome, Whipple disease, inflammatory bowel disease, intestinal polyp, necrotizing enterocolitis, intestinal perforation, neurogenic bowel, pneumatosis cystoides intestinalis, volvulus of midgut, abetalipoproteinemia, aplasia cutis congenita-intestinal lymphangiectasia syndrome, trichohepatoenteric syndrome, protein-losing enteropathy, chronic diarrhea with villous atrophy, Satoyoshi syndrome, glucose-galactose malabsorption, congenital diarrhea 7 with exudative enteropathy, chronic atrial and intestinal dysrhythmia, congenital enterocyte heparan sulfate deficiency, short bowel syndrome, intractable diarrhea-choanal atresia-eye anomalies syndrome, solitary rectal ulcer syndrome, NK-cell enteropathy, chronic intestinal failure, intestinal lymphangiectasia, refractory celiac disease, eosinophilic gastrointestinal disease, cryptogenic multifocal ulcerous stenosing enteritis, chronic enteropathy associated with SLCO2A1 gene, cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder, malakoplakia, malabsorption syndrome, ischemic bowel disorder, intestinal motility disease, 4-hydroxyphenylacetic aciduria, parasitic intestinal disorder, Aeromonas hydrophila intestinal disease, large intestine disorder, small intestine disorder, primary desmosis coli, isolated mesenteric vein thrombosis, collagenous sprue, visceral leiomyopathy, African degenerative, intestinal dysmotility syndrome, intestinal fistula

Subtypes (6): intestinal neuroendocrine neoplasm, intestinal benign neoplasm, small intestine neoplasm, colorectal neoplasm, intestinal cancer, epithelial tumor of anal canal

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 27.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	13
PHASE2	9
PHASE3	4
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07222800	PHASE3	RECRUITING	Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT00994903	PHASE3	COMPLETED	Simvastatin in Colorectal Surgery
NCT01996306	PHASE3	COMPLETED	A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
NCT03303495	PHASE3	UNKNOWN	A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
NCT04755920	PHASE2	RECRUITING	SGM-101 in Colorectal Brain Metastases.
NCT01037049	PHASE2	UNKNOWN	Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
NCT02202928	PHASE2	UNKNOWN	Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
NCT03037385	PHASE1/PHASE2	COMPLETED	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03271255	PHASE2	UNKNOWN	Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
NCT03280407	PHASE2	UNKNOWN	NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
NCT03559543	PHASE2	COMPLETED	Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
NCT04080843	PHASE2	COMPLETED	Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
NCT04644315	PHASE2	TERMINATED	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
NCT05193292	PHASE2	UNKNOWN	Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
NCT04949282	Not specified	RECRUITING	Spanish Series of Patients Treated With the Radionuclide Lutetium177
NCT05551052	Not specified	ACTIVE_NOT_RECRUITING	CRC Detection Reliable Assessment With Blood
NCT01910974	Not specified	COMPLETED	Multicentric Study an Endoscopic Treatment of Digestive Neoplasia by Submucosal Dissection Evaluation of a New Water Jet System
NCT01995942	Not specified	UNKNOWN	Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
NCT02005965	Not specified	UNKNOWN	Low Rectal Cancer Study (MERCURY II)
NCT02785783	Not specified	COMPLETED	Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
NCT03072472	Not specified	COMPLETED	BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities
NCT03659357	Not specified	UNKNOWN	Study of Small Bowel Tumor With Dual-phase Enhanced Computed Tomography (CTE) and Magnetic Resonance Enterography (MRE)
NCT04673136	Not specified	COMPLETED	Usefulness of GI-GENIUS in FIT-based Colorectal Cancer Screening Program.
NCT04744688	Not specified	COMPLETED	Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
NCT05322486	Not specified	UNKNOWN	Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
NCT06048146	Not specified	COMPLETED	A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis
NCT06260150	Not specified	UNKNOWN	Application of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALECTINIB	4	1
IRINOTECAN HYDROCHLORIDE	4	1
PRALSETINIB	4	1
SIMVASTATIN	4	1
CATEQUENTINIB HYDROCHLORIDE	3	1
CHEMBL4297597	0	1
CHEMBL5572229	0	1